174 related articles for article (PubMed ID: 35105722)
1. Low-dose belimumab for patients with systemic lupus erythematosus at low disease activity: protocol for a multicentre, randomised, double-blind, placebo-controlled clinical trial.
Sun F; Huang W; Chen J; Zhao L; Zhang D; Wang X; Wan W; Dai SM; Chen S; Li T; Ye S
Lupus Sci Med; 2022 Feb; 9(1):. PubMed ID: 35105722
[TBL] [Abstract][Full Text] [Related]
2. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
Loncharich MF; Anderson CW
ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.
Navarra SV; Guzmán RM; Gallacher AE; Hall S; Levy RA; Jimenez RE; Li EK; Thomas M; Kim HY; León MG; Tanasescu C; Nasonov E; Lan JL; Pineda L; Zhong ZJ; Freimuth W; Petri MA;
Lancet; 2011 Feb; 377(9767):721-31. PubMed ID: 21296403
[TBL] [Abstract][Full Text] [Related]
4. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
Furie R; Petri M; Zamani O; Cervera R; Wallace DJ; Tegzová D; Sanchez-Guerrero J; Schwarting A; Merrill JT; Chatham WW; Stohl W; Ginzler EM; Hough DR; Zhong ZJ; Freimuth W; van Vollenhoven RF;
Arthritis Rheum; 2011 Dec; 63(12):3918-30. PubMed ID: 22127708
[TBL] [Abstract][Full Text] [Related]
5. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.
Teng YKO; Bruce IN; Diamond B; Furie RA; van Vollenhoven RF; Gordon D; Groark J; Henderson RB; Oldham M; Tak PP
BMJ Open; 2019 Mar; 9(3):e025687. PubMed ID: 30898822
[TBL] [Abstract][Full Text] [Related]
6. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
Petri MA; van Vollenhoven RF; Buyon J; Levy RA; Navarra SV; Cervera R; Zhong ZJ; Freimuth WW;
Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628
[TBL] [Abstract][Full Text] [Related]
7. Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial.
Jones A; Muller P; Dore CJ; Ikeji F; Caverly E; Chowdhury K; Isenberg DA; Gordon C; Ehrenstein MR
BMJ Open; 2019 Dec; 9(12):e032569. PubMed ID: 31848169
[TBL] [Abstract][Full Text] [Related]
8. Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial.
Tanaka Y; Bass D; Chu M; Egginton S; Ji B; Roth D
Mod Rheumatol; 2020 Mar; 30(2):313-320. PubMed ID: 31199180
[No Abstract] [Full Text] [Related]
9. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea.
Zhang F; Bae SC; Bass D; Chu M; Egginton S; Gordon D; Roth DA; Zheng J; Tanaka Y
Ann Rheum Dis; 2018 Mar; 77(3):355-363. PubMed ID: 29295825
[TBL] [Abstract][Full Text] [Related]
10. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.
Wallace DJ; Stohl W; Furie RA; Lisse JR; McKay JD; Merrill JT; Petri MA; Ginzler EM; Chatham WW; McCune WJ; Fernandez V; Chevrier MR; Zhong ZJ; Freimuth WW
Arthritis Rheum; 2009 Sep; 61(9):1168-78. PubMed ID: 19714604
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.
Stohl W; Schwarting A; Okada M; Scheinberg M; Doria A; Hammer AE; Kleoudis C; Groark J; Bass D; Fox NL; Roth D; Gordon D
Arthritis Rheumatol; 2017 May; 69(5):1016-1027. PubMed ID: 28118533
[TBL] [Abstract][Full Text] [Related]
12. The effect of 24-week belimumab treatment withdrawal followed by treatment restart in patients with SLE: an open-label, non-randomised 52-week study.
Bae SC; Bass DL; Chu M; Curtis P; Dimelow R; Harvey L; Ji B; Kurrasch R; Muzaffar S; Punwaney R; Roth DA; Song YW; Xie W; Zhang F
Arthritis Res Ther; 2022 Feb; 24(1):46. PubMed ID: 35172878
[TBL] [Abstract][Full Text] [Related]
13. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials.
Manzi S; Sánchez-Guerrero J; Merrill JT; Furie R; Gladman D; Navarra SV; Ginzler EM; D'Cruz DP; Doria A; Cooper S; Zhong ZJ; Hough D; Freimuth W; Petri MA;
Ann Rheum Dis; 2012 Nov; 71(11):1833-8. PubMed ID: 22550315
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy-Six-Week Phase III Parent Study in the United States.
Furie RA; Wallace DJ; Aranow C; Fettiplace J; Wilson B; Mistry P; Roth DA; Gordon D
Arthritis Rheumatol; 2018 Jun; 70(6):868-877. PubMed ID: 29409143
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of metformin in systemic lupus erythematosus: a multicentre, randomised, double-blind, placebo-controlled trial.
Sun F; Wang HJ; Liu Z; Geng S; Wang HT; Wang X; Li T; Morel L; Wan W; Lu L; Teng X; Ye S
Lancet Rheumatol; 2020 Apr; 2(4):e210-e216. PubMed ID: 38268156
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Subcutaneous Belimumab in Anti-Double-Stranded DNA-Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus.
Doria A; Stohl W; Schwarting A; Okada M; Scheinberg M; van Vollenhoven R; Hammer AE; Groark J; Bass D; Fox NL; Roth D; Gordon D
Arthritis Rheumatol; 2018 Aug; 70(8):1256-1264. PubMed ID: 29671280
[TBL] [Abstract][Full Text] [Related]
17. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE).
Kalunian KC; Merrill JT; Maciuca R; McBride JM; Townsend MJ; Wei X; Davis JC; Kennedy WP
Ann Rheum Dis; 2016 Jan; 75(1):196-202. PubMed ID: 26038091
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of intravenous belimumab in a subgroup of South Korean patients with systemic lupus erythematosus enrolled into a Phase 3, randomized, placebo-controlled trial in North East Asia.
Suh CH; Lee Y; Yoo SB; Quasny H; Navarro Rojas AA; Hammer A; Song YW; Kang YM; Cho CS; Park W; Kwok SK; Lee SG; Chung WT; Bae SC
Int J Rheum Dis; 2024 Jan; 27(1):e14997. PubMed ID: 38140854
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison.
Brunner HI; Abud-Mendoza C; Mori M; Pilkington CA; Syed R; Takei S; Viola DO; Furie RA; Navarra S; Zhang F; Bass DL; Eriksson G; Hammer AE; Ji BN; Okily M; Roth DA; Quasny H; Ruperto N
RMD Open; 2021 Sep; 7(3):. PubMed ID: 34531304
[TBL] [Abstract][Full Text] [Related]
20. The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis.
Wilkinson C; Henderson RB; Jones-Leone AR; Flint SM; Lennon M; Levy RA; Ji B; Bass DL; Roth D
Arthritis Res Ther; 2020 May; 22(1):102. PubMed ID: 32366280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]